POLICY PRIORITIES - APPLICATION 1
Delphi Results
Synthetic Biomaterials
Development, production and sale of synthetic biomaterials for clinical applications in human health
Plausibly available in the immediate future
(up to 5 years from now)
BENEFITS AND COSTS
​
​
What benefits are most relevant?
​
1. Strengthen basic biological research that is more relevant to human subjects than to animal models (μ=7,36; SD=1,37)
2. Biological solutions to the problem of shortage of human organs and tissues” (μ=7,04; SD=1,14)
​
Which stakeholders will mostly benefit?
​
1. Private biotechnology firms (μ=7,93; SD=1,15)
2. Patient’s organizations (μ=6,89; SD=1,31)
​
​
What costs are most relevant?
​
1. Difficulty to predict the long-term biological behaviour of synthetic biomaterials implanted in the human body (μ=6,89; SD=1,31)
2. Rise of new ethical issues concerning the production of artificial cells, tissues and organs (μ=6,64; SD=1,59)
​
​
Which stakeholders will have to bear the highest costs ?
​
1. National public health agencies (μ=6,32; SD=1,72)
2. Private biotechnology firms” (μ=6,04; SD=1,82)
​
​
Which stakeholders can have a relevant role in the allocation of costs and benefits ?
1. Policy Makers
2. Research Fundings
​
Which procedure should be used to asses the costs and benefits of the application?
1. Risk Assessment Procedures
​
​
​
GOVERNANCE AND REGULATORY TOOLS
​
Which governance framework should be used to regulate R&D activities ?
​
1. International guidelines” (μ=7,54; SD=1,10)
​
​
Which procedures should be used to foster compliance with regulatory measures ?
​
1. Legally binding procedures
2. Regularly monitored and evaluated through audit procedures
​
​
Which approaches are most useful in encouraging companies and research organization to comply with regulatory and governance?
​
1. Reputational Incentives (ethical labels, brands, and rankings) (μ=7,00; SD=1,41)
2. Requirement to integrate the adherence to the regulatory measures into research funding through evaluation criteria (μ=6,61; SD=1,34)
​
​
​